- 12/03/2018IR
〔Summary〕Asset Purchase Agreement of Tb535H and Trisoma technology
〔Summary〕Asset Purchase Agreement of Tb535H and Trisoma technology
- 11/14/2018IR
Supplement Documents for Financial Results Q3 FY12/18
Supplement Documents for Financial Results Q3 FY12/18
- 08/14/2018IR
Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2018
Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2018
- 08/14/2018IR
Supplement Documents for Financial Results Q2 FY12/18
Supplement Documents for Financial Results Q2 FY12/18
- 08/14/2018IR
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2018
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2018
- 05/15/2018IR
Supplement Documents for Financial Results Q1 FY12/18
Supplement Documents for Financial Results Q1 FY12/18
- 05/15/2018IR
Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31, 2018
Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31, 2018
- 03/22/2018IR
Execution of the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody developed by Chiome Bioscience
Execution of the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody developed by Chiome Bioscience
- 02/14/2018IR
Supplement Documents for Financial Results FY12/17
Supplement Documents for Financial Results FY12/17
- 02/14/2018IR
Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2017
Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2017
- Top
- News